The Companycompany develops internationally competitive innovative drugs targeting selected therapeutic areas andspecific targets in specific niche fields. Through a professional, focused, and international R&Dresearch approachand development strategies, it has established ana end-to-endcomplete technologytechnical system covering the entire process from early drug discovery to commercialization. ItsThrough Compoundthe Screeningcompound Platformscreening platform, Newnew Drugdrug Evaluationevaluation Platformplatform, Blood-brainblood-brain Barrierbarrier Penetrationpenetration Technologytechnology Platformplatform, Polypeptidepeptide Drugdrug Technologytechnology Platformplatform, and Targetedtargeted Proteinprotein Degradationdegradation Technologytechnology Platform supportplatform, the discoverycompany has identified and screening ofscreened new candidate compounds andfor relevant targets, establishing a diversified,diverse independently developedR&D pipeline ofwith small-moleculeindependent intellectual property rights, covering small molecule innovative drugs and biologicsbiopharmaceuticals.

InBy 2026, Haisco is expanding itsthe core innovation capabilitiesplatforms intowill biologicsexpand to include biopharmaceuticals and small nucleic acids, byas buildingwell Macromoleculeas macromolecular and Smallsmall Nucleicnucleic Acidacid platforms. Nine pipelines arewill advancing progressingbe inadvanced parallelsimultaneously, alongsidealong with the establishment of an in situ CAR-T (In vivo CAR-T) drug R&D platform designedthat forfeatures low immunogenicity and efficient targeted delivery. Since the beginningAs of 2026, the Groupgroup has received two Breakthroughnew Therapybreakthrough Designations;therapeutic drugs recognized, one marketing application hasis enteredincluded in the priority review and approval process;, and one project has been selected for the CDE "Starlight Plan;Program". andAt key filing milestones, three NDAsNDA applications have been filedsubmitted.